New dosing strategy aims to cut transfusions for kids with sickle cell disease
NCT ID NCT05662098
First seen Apr 14, 2026 · Last updated Apr 25, 2026 · Updated 2 times
Summary
This study looks at whether giving hydroxyurea based on a child's unique body chemistry can lower the need for blood transfusions in children with sickle cell anemia. About 100 children aged 1 to 10 years will receive the drug and be monitored. The goal is to make treatment more effective and reduce complications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jinja Regional Referral Hospital (JRRH), Department of Paediatrics, Sickle Cell Clinic
Jinja, Uganda
Conditions
Explore the condition pages connected to this study.